Neurosurgery was Integra Lifesciences Holdings’s largest product and service line in fiscal 2025, bringing in $827.67M of $1.64B (51%).
| Product and Service | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurosurgery | $794.02M | $818.10M | $803.82M | $827.67M | |||||||||||
| Wound Reconstruction & Care | $406.69M | $373.99M | $350.57M | $323.49M | |||||||||||
| Wound Reconstruction | — | — | — | — | |||||||||||
| Orthopedics | — | — | — | — | |||||||||||
| Specialty Surgical Solutions | — | — | — | — | |||||||||||
| U.S. Neurosurgery | — | — | — | — | |||||||||||
| Instruments | $192.68M | $203.62M | $204.18M | $206.47M | |||||||||||
| Precision Tools & Instruments | — | — | — | — | |||||||||||
| International | — | — | — | — | |||||||||||
| Orthopedics & Tissue Technologies | — | — | — | — | |||||||||||
| U.S. Instruments | — | — | — | — | |||||||||||
| U.S. Spine & Other | — | — | — | — | |||||||||||
| Private Label | $131.41M | $108.59M | $116.33M | $111.25M | |||||||||||
| U.S. Extremities | — | — | — | — | |||||||||||
| Ent | $32.87M | $37.28M | $135.64M | $166.37M | |||||||||||
| Extremity Orthopedics | — | — | — | — | |||||||||||
| Total | $1.56B | $1.54B | $1.61B | $1.64B |
Integra Lifesciences Holdings brought in $1.64B from its five product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 1.5% from $1.61B in fiscal 2024. Neurosurgery was the largest at $827.67M (50.6%), ahead of Wound Reconstruction & Care at $323.49M (19.8%) and Instruments at $206.47M (12.6%). The other two lines brought in $277.62M combined.
Compared with fiscal 2024, Ent grew fastest, up 22.7% to $166.37M, while Wound Reconstruction & Care fell the most, down 7.7% to $323.49M. From fiscal 2022 to 2025, combined revenue from these lines grew from $1.56B to $1.64B, a compound annual growth rate of 1.6%. Neurosurgery's share held steady at about 50.6%.
United States was Integra Lifesciences Holdings’s largest region in fiscal 2025, bringing in $1.20B of $1.64B (74%).
| Geography | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.13B | $1.10B | $1.19B | $1.20B | ||||||||||||
| United States (Includes Long-Lived Assets In Puerto Rico) | — | — | — | — | ||||||||||||
| Asia Pacific | $176.48M | $193.10M | $176.61M | $189.25M | ||||||||||||
| Europe | $170.90M | $165.22M | $158.50M | $162.67M | ||||||||||||
| Rest Of World | — | — | — | — | ||||||||||||
| Rest Of The World | $83.48M | $82.53M | $82.74M | $78.58M | ||||||||||||
| Total | $1.56B | $1.54B | $1.61B | $1.64B |
Integra Lifesciences Holdings brought in $1.64B from its four regions in fiscal 2025, the year ended December 31, 2025. That was up 1.5% from $1.61B in fiscal 2024. United States was the largest at $1.20B (73.7%), ahead of Asia Pacific at $189.25M (11.6%) and Europe at $162.67M (9.9%). The remaining region, Rest Of The World, brought in $78.58M.
Compared with fiscal 2024, Asia Pacific grew fastest, up 7.2% to $189.25M, while Rest Of The World fell the most, down 5.0% to $78.58M. From fiscal 2022 to 2025, combined revenue from these regions grew from $1.56B to $1.64B, a compound annual growth rate of 1.6%. United States' share of the total rose from 72.3% to 73.7%.
Codman Specialty Surgical was Integra Lifesciences Holdings’s largest segment in fiscal 2025, bringing in $1.20B of $1.64B (73%).
| Segment | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Codman Specialty Surgical | $1.02B | $1.06B | $1.14B | $1.20B | ||||||||
| Specialty Surgical Solutions | — | — | — | — | ||||||||
| Tissue Technologies | $538.10M | $482.58M | $466.89M | $434.73M | ||||||||
| Orthopedics & Tissue Technologies | — | — | — | — | ||||||||
| Total | $1.56B | $1.54B | $1.61B | $1.64B |
Integra Lifesciences Holdings brought in $1.64B from its two segments in fiscal 2025, the year ended December 31, 2025. That was up 1.5% from $1.61B in fiscal 2024. Codman Specialty Surgical was the largest at $1.20B (73.4%), ahead of Tissue Technologies at $434.73M (26.6%).
Compared with fiscal 2024, Codman Specialty Surgical grew 5.0% to $1.20B, while Tissue Technologies fell 6.9% to $434.73M. From fiscal 2022 to 2025, combined revenue from these segments grew from $1.56B to $1.64B, a compound annual growth rate of 1.6%. Codman Specialty Surgical's share of the total rose from 65.5% to 73.4%.
Integra Lifesciences Holdings (IART) reports its revenue by product and service, by geography and by segment. In fiscal 2025, Neurosurgery was its largest product and service line, bringing in $827.67M (50.6% of the total), followed by Wound Reconstruction & Care at $323.49M (19.8%).
Neurosurgery was Integra Lifesciences Holdings' largest product and service line in fiscal 2025, bringing in $827.67M, or 50.6% of the $1.64B total across its five product and service lines.
United States was Integra Lifesciences Holdings' largest region in fiscal 2025, bringing in $1.20B, or 73.7% of the $1.64B total across its four regions.
Codman Specialty Surgical was Integra Lifesciences Holdings' largest segment in fiscal 2025, bringing in $1.20B, or 73.4% of the $1.64B total across its two segments.
Among Integra Lifesciences Holdings' product and service lines that make up at least 2% of revenue, Ent grew fastest in fiscal 2025, up 22.7% from $135.64M to $166.37M.
Every figure comes from Integra Lifesciences Holdings' annual financial filings, as reported. Each line keeps the name Integra Lifesciences Holdings gives it, and years follow its fiscal calendar.
Integra Lifesciences Holdings' revenue by product and service goes back to fiscal 2009, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.